Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how

    Research output: Contribution to journalReviewResearchpeer-review

  3. Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Considerations on the strengths and limitations of using disease-related mortality as an outcome in clinical research

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Early specialised palliative care: interventions, symptoms, problems

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder with estimated global prevalence rates between 3% and 5% in children and 2.5% in adults, depending on the classification system used. The psychostimulant methylphenidate is one of the most frequently used medications for ADHD. In this analysis article we describe shortly the evidence in the field, an application for inclusion of methylphenidate on the WHO Model List of Essential Medicines, the comments raised to the application and the WHO Expert Committee's decision. The application of getting methylphenidate on the WHO list was overzealous in reporting potential benefits, without highlighting key uncertainties and harms. Decisions encompassing medicines candidate to the WHO Model List should not be based on speculation about potential benefits and should fully incorporate areas of uncertainties. Even though methylphenidate has been used for over 60 years, the evidence concerning the benefits of this medication in children, adolescents and adults with ADHD is uncertain. The decision of the committee was to not include methylphenidate in the WHO Model List of Essential Medicines 'due to uncertainties in the estimates of benefit, and concerns regarding the quality and limitations of the available evidence for both benefit and harm'.

Original languageEnglish
JournalBMJ Evidence-Based Medicine
Volume26
Issue number4
Pages (from-to)172-175
Number of pages4
ISSN1356-5524
DOIs
Publication statusPublished - 1 Aug 2021

    Research areas

  • adult psychiatry, child & adolescent psychiatry, psychiatry

ID: 59736352